Showing results (581-590 of 603) with videos related to
Sort By:
Pageof 61
Blood|April 22, 2020
Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphomaRenate De Smedt, Julie Morscio, Lindy Reunes, et al.The Lancet. Oncology|November 19, 2011
Meningiomas in children and adolescents: a meta-analysis of individual patient dataRishi S Kotecha, Elaine M Pascoe, Elisabeth J Rushing, et al.Science Advances|April 29, 2026
IRS4 is a PI3K-activating cancer dependency up-regulated through DNA rearrangements or epigenetic mechanisms in multiple solid tumorsKhadija Banu, Mohammad Aslam Khan, Sihan Li, et al.Frontiers in Oncology|June 9, 2022
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia ProgressionLin Xiao, Mawar Karsa, Emma Ronca, et al.NPJ Genomic Medicine|February 17, 2025
Returning raw genomic data to research participants in a pediatric cancer precision medicine trialKristine Barlow-Stewart, Eliza Courtney, Mark Cowley, et al.European Journal of Cancer (Oxford, England : 1990)|November 17, 2021
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocolJ Stutterheim, P de Lorenzo, I M van der Sluis, et al.Journal for Immunotherapy of Cancer|February 5, 2026
Shared PRAME epitopes are T-cell targets in NUT carcinomaJeffrey L Jensen, Sara K Peterson, Maria J Sambade, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 ProtocolJanine Stutterheim, Inge M van der Sluis, Paola de Lorenzo, et al.Leukemia|November 15, 2022
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategyLaurence C Cheung, Carlos Aya-Bonilla, Mark N Cruickshank, et al.Science Translational Medicine|May 17, 2023
Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemiaErnest Moles, Christopher B Howard, Pie Huda, et al.Pageof 61